Therapeutic Advances in Psychopharmacology

Papers
(The median citation count of Therapeutic Advances in Psychopharmacology is 3. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-04-01 to 2025-04-01.)
ArticleCitations
Drug safety in older patients with alcohol use disorder: a retrospective cohort study44
Olanzapine long-acting injection, discontinuation rates and reasons for discontinuation: 10 years’ experience at a UK high-secure hospital29
Exploring the clinical factors affecting lithium dose and plasma level and the effect of brand28
Analysis of the clinical characteristics of olanzapine-induced acute pancreatitis27
Tardive dyskinesia: understanding current challenges in diagnosis and treatment26
Antipsychotic polypharmacy and clozapine prescribing patterns: evolution and correlates before and after a psychiatric hospitalisation24
Real-life effectiveness of transitioning from paliperidone palmitate 1-monthly to paliperidone palmitate 3-monthly long-acting injectable formulation24
Hypercoagulable state in patients with schizophrenia: different effects of acute and chronic antipsychotic medications23
Prevalence and predictors of inappropriate prescribing in outpatients with severe mental illness22
Risperidone-induced neuroleptic malignant syndrome: a case report21
Increased amisulpride serum concentration in a patient treated with concomitant pregabalin and trazodone: a case report19
Metformin co-commencement at time of antipsychotic initiation for attenuation of weight gain: a systematic review and meta-analysis16
Will psilocybin lose its magic in the clinical setting?16
Effect of long-acting injectable antipsychotics on hospitalizations and global functioning in schizophrenia: a naturalistic mirror-image study15
History repeating: guidelines to address common problems in psychedelic science14
Plasma levels of interleukin-6 and 3-methoxy-4-hydroxyphenylglycol and treatment with milnacipran in major depression13
Low-frequency repetitive transcranial magnetic stimulation for the treatment of post-traumatic stress disorder and its comparison with high-frequency stimulation: a systematic review and meta-analysis12
Corrigendum to ‘Comment on: History repeating: guidelines to address common problems in psychedelic science’12
Ketamine and esketamine in suicidal thoughts and behaviors: a systematic review11
Sublingual asenapine for agitation in malabsorptive states: three patient cases10
Preventing and treating delirium in clinical settings for older adults10
Clozapine/norclozapine plasma level ratio and cognitive functioning in patients with schizophrenia spectrum disorders: a systematic review10
A 6-week, phase IIb, randomized, double-blind, placebo-controlled trial of Anyu Peibo capsules for the treatment of major depressive disorder in adults9
Comparative effectiveness study of paliperidone palmitate 6-month with a real-world external comparator arm of paliperidone palmitate 1-month or 3-month in patients with schizophrenia8
Oral and long-acting injectable antipsychotic discontinuation and relationship to side effects in people with first episode psychosis: a longitudinal analysis of electronic health record data8
Comment on: History repeating: guidelines to address common problems in psychedelic science8
The cardiovascular safety of tricyclic antidepressants in overdose and in clinical use8
The clinical effectiveness and cost effectiveness of clozapine for inpatients with severe borderline personality disorder (CALMED study): a randomised placebo-controlled trial7
Management of dyslipidaemia in individuals with severe mental illness: a population-based study in the Greater Copenhagen Area7
Risperidone ISM®: review and update of its usefulness in all phases of schizophrenia6
Pathophysiology, prognosis and treatment of tardive dyskinesia6
Disrupted emotion regulation and spontaneous neural activity in panic disorder: a resting-state fMRI study6
Agomelatine for the treatment of generalized anxiety disorder: focus on its distinctive mechanism of action6
Current perspectives on the epidemiology and burden of tardive dyskinesia: a focused review of the clinical situation in Japan5
The psychedelic afterglow phenomenon: a systematic review of subacute effects of classic serotonergic psychedelics5
Efficacy of intraoperative subanesthetic dose of ketamine/esketamine in preventing postoperative cognitive dysfunction: a systematic review and meta-analysis5
Duration of prior psychotic illness and clozapine response: a retrospective observational study using electronic health records5
Exercise interventions to reduce anxiety in mid-life and late-life anxiety disorders and subthreshold anxiety disorder: a systematic review5
Neuroimaging features of cognitive impairments in schizophrenia and major depressive disorder5
Who is prescribed valproate and how carefully is this treatment reviewed in UK mental health services? Data from a clinical audit5
Clozapine- and non-clozapine-associated neutropenia in patients with schizophrenia: a retrospective cohort study5
Vortioxetine as adjunctive therapy in the treatment of schizophrenia4
Long-acting injectable antipsychotics for the treatment of bipolar disorder: evidence from mirror-image studies4
Clozapine-induced cholinergic urticaria: a case report4
Use of an injection of aripiprazole given once every 2 months (Abilify Asimtufii®) in people with bipolar I disorder: a Plain Language Summary of Publication4
Gut microbiome in schizophrenia and antipsychotic-induced metabolic alterations: a scoping review4
Psychosocial interventions to improve adherence in depressed and anxious older adults prescribed antidepressant pharmacotherapy: a scoping review4
Serum cytokine variations among inpatients with major depression, bipolar disorder, and schizophrenia versus healthy controls: a prospective ‘true-to-life’ study4
Identifying dopamine supersensitivity through a randomized controlled study of switching to aripiprazole from other antipsychotic agents in patients with schizophrenia3
Using in silico methods to determine optimal tapering regimens for decanoate-based long-acting injectable psychosis drugs3
Anticholinergic action is rarely a good thing3
Efficacy and safety of long-acting injectable versus oral antipsychotics in the treatment of patients with early-phase schizophrenia-spectrum disorders: a systematic review and meta-analysis3
Can the use of long-acting injectable antipsychotic preparations be increased in routine clinical practice and the benefits realised?3
Incidence of hyperthyroidism in patients with bipolar or schizoaffective disorder with or without lithium: 21-year follow-up from the LiSIE retrospective cohort study3
Dose-response analysis of aripiprazole in patients with schizophrenia in Taiwan3
Time to rehospitalization in involuntarily hospitalized individuals suffering from schizophrenia discharged on long-acting injectable antipsychotics or oral antipsychotics3
Efficacy and safety of cariprazine augmentation in patients treated with clozapine: a pilot study3
Network analysis of the comorbidity between post-traumatic stress, depression and anxiety symptoms among frontline healthcare workers during the COVID-19 pandemic3
The potential of ketamine for posttraumatic stress disorder: a review of clinical evidence3
Ketamine for bipolar depression: an updated systematic review3
0.10235905647278